Acurex Biosciences Awarded ASAP Grant to Advance Breakthrough Approach to Parkinson’s Disease
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson’s disease
Acurex Biosciences, a biotechnology company developing new medicines for Parkinson’s disease and other neurological disorders, today announced it has been awarded a grant from Aligning Science Across Parkinson’s (ASAP) in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
The award will support a multi-year collaboration, including Professor Sarah Marzi of King’s College London and Professor Emily Rocha of the University of Pittsburgh, and led by Professor Tim Greenamyre, MD, PhD, also of the University of Pittsburgh, who is one of the world’s leading Parkinson’s disease researchers. The team will join theCollaborative Research Network (CRN), an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson’s disease.
Parkinson’s disease affects nearly 10 million people worldwide. While current medicines can help manage symptoms, none have been proven to slow or stop the underlying progression of the disease. Acurex is focused on advancing research into the underlying biology of the disease.
